ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
HCW Biologics Inc. (HCWB) stock declined over -193.55%, trading at $0.33 on NASDAQ, down from the previous close of $0.34. The stock opened at $0.36, fluctuating between $0.33 and $0.37 in the recent session.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Employees | 45 |
Beta | 0.71 |
Sales or Revenue | $2.84M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |